scholarly journals Prognostic Value and Clinicopathological Features of MicroRNA-206 in Various Cancers: A Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Rongqiang Liu ◽  
Shiyang Zheng ◽  
Shengjia Peng ◽  
Yajie Yu ◽  
Jianwen Fang ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Web Of Science ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Prognostic Indicator ◽  
Tumor Stage ◽  
Clinicopathological Features ◽  
Lymph Node Status ◽  
Invasion Depth ◽  
Hazard Ratios

It has been reported that microRNA-206(miR-206) plays an important role in cancers and could be used as a prognostic biomarker. However, the results are controversial. Therefore, we summarize all available evidence and present a meta-analysis to estimate the prognostic value of miR-206 in various cancers. The relevant studies were collected by searching PubMed, EMBASE, and Web of Science databases until August 21, 2020. Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were applied to explore the association between miR-206 and survival results and clinicopathologic features. Sources of heterogeneity were investigated by subgroup analysis and sensitivity analysis. Publication bias was evaluated using Egger’s test. Twenty articles involving 2095 patients were included in the meta-analysis. The pooled HR showed that low miR-206 expression was significantly associated with unfavourable overall survival (OS) ( HR = 2.03 , 95 CI%: 1.53-2.70, P < 0.01 ). In addition, we found that low miR-206 expression predicted significantly negative association with tumor stage (III-IV VS. I-II) ( OR = 4.20 , 95% CI: 2.17-8.13, P < 0.01 ), lymph node status (yes VS. no) ( OR = 3.58 , 95%: 1.51-8.44, P = 0.004 ), distant metastasis (yes VS. no) ( OR = 3.19 , 95%: 1.07-9.50, P = 0.038 ), and invasion depth ( T 3 + T 4 vs. T 2 + T 1 ) ( OR = 2.43 , 95%: 1.70-3.49, P < 0.01 ). miR-206 can be used as an effective prognostic indicator in various cancers. Further investigations are warranted to validate the present results.

scholarly journals Prognostic Value of Circular RNA ciRS-7 in Various Cancers: A PRISMA-Compliant Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-9 ◽  
Author(s):  
Guangwei Tian ◽  
Guang Li ◽  
Lin Guan ◽  
Zihui Wang ◽  
Nan Li
Keyword(s):  
Meta Analysis ◽  
Prognostic Indicator ◽  
Tumor Stage ◽  
Circular Rna ◽  
Cochrane Library ◽  
Size Analysis ◽  
Circular Rnas ◽  
Hazard Ratios ◽  
Potential Biomarker ◽  
The Cochrane Library

Background. Circular RNAs (circRNAs) have been shown to be involved in tumorigenesis. As a member of circRNAs, ciRS-7 is thought to be a negative prognostic indicator in multiple types of cancer. The present study aimed to comprehensively explore the value of ciRS-7 in tumor malignancy. Materials and Methods. A systematic review of PubMed, Web of Science, and the Cochrane library was carried out to examine the related studies. The pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated from the available publications by STATA 12.0. Subgroup analysis, publication bias, sensitivity analysis, and meta-regression were conducted. Results. This meta-analysis included 1,714 patients from 13 cohorts. The results suggested that high ciRS-7 expression was significantly associated with overall survival (OS) (HR = 2.17, 95% CI = 1.50–3.15, P<0.001) in various cancers. Stratified analyses indicated that elevated levels of ciRS-7 appeared to be a powerful prognostic biomarker for patients with non-small-cell lung cancer (NSCLC) (HR: 2.50, 95% CI: 1.07–6.07, P=0.035), colorectal cancer (CRC) (HR: 1.95, 95% CI: 1.34–2.84, P<0.001), and gastric cancer (GC) (HR: 2.32, 95% CI: 1.48–3.64, P<0.001). A similar effect was also observed in subgroup of sample size, analysis method, and cutoff value, except for ethnicity. The increased ciRS-7 expression was associated with a higher tumor stage (OR = 2.30, 95% CI: 1.69–3.13, P<0.001). Conclusions. High expression of ciRS-7 has a significant correlation with the high stage in various cancers, and ciRS-7 is intimately associated with an adverse OS in numerous cancers. Thus, ciRS-7 may act as a potential biomarker for the development of malignancies.

scholarly journals Association of STMN1 with survival in solid tumors: A systematic review and meta-analysis

2019 ◽  
Vol 34 (2) ◽  
pp. 108-116
Author(s):  
Dan Zhang ◽  
Lizhen Dai ◽  
ZengXi Yang ◽  
XiChen Wang ◽  
Yin LanNing
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Endometrial Cancer ◽  
Solid Tumors ◽  
Prognostic Value ◽  
Web Of Science ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Sensitivity Analyses ◽  
Poor Overall Survival

Background: The prognostic value of Stathmin 1 (STMN1) in malignant solid tumors remains controversial. Thus, we conducted this meta-analysis to summarize the potential value of STMN1 as a biomarker for predicting overall survival in patients with solid tumor. Methods: We systematically searched eligible studies in PubMed, Web of Science, and EMBASE from the establishment date of these databases to September 2018. Hazard ratio (HR) and its 95% confidence interval (CI) was used to assess the association between STMN1 expression and overall survival. Results: A total of 25 studies with 4625 patients were included in this meta-analysis. Our combined results showed that high STMN1 expression was associated with poor overall survival in solid tumors (HR = 1.85, 95% CI 1.55, 2.21). In general, our subgroup and sensitivity analyses demonstrated that our combined results were stable and reliable. However, from the results of the subgroups we found that high STMN1 expression was not related to overall survival in colorectal cancer and endometrial cancer anymore, suggesting that much caution should be taken to interpret our combined result, and more studies with large sample sizes are required to further explore the prognostic value of STMN1 expression in the specific type of tumors, especially colorectal cancer and endometrial cancer. Conclusions: STMN1 could serve as a prognostic biomarker and could be developed as a valuable therapeutic target for patients with solid tumors. However, due to the limitations of the present meta-analysis, this conclusion should be taken with caution. Further studies adequately designed are required to confirm our findings.

scholarly journals Clinicopathological and Prognostic Value of SNHG6 in Cancers: a Systematic Review and a Meta-analysis

2020 ◽  
Author(s):  
Shuo Zhang ◽  
Dandan Qiu ◽  
Xiaohong Xie ◽  
Yong Shen
Keyword(s):  
Tumor Invasion ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Tnm Stage ◽  
Invasion Depth ◽  
Clinical Value ◽  
Human Cancers ◽  
Hazard Ratios ◽  
Non Coding Rna ◽  
Tumor Invasion Depth

Abstract Background: The long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG6) is dysregulated in various malignant tumor. However, a definite conclusion on the clinical value of lncRNA SNHG6 expression in human cancers has not been determined. The purpose of the present meta-analysis was to comprehensively elucidate the association between SNHG6 expression and clinical outcomes in cancers.Methods: A systematic search was performed through the PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wangfang databases for relevant studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were collected to estimate the prognostic value, and the odds ratios (ORs) with 95% CIs were used to evaluate the relationship between lncRNA SNHG6 expression and clinicopathological features, including tumor invasion depth, lymph node metastasis (LNM), distance metastasis (DM), and TNM stage. Results: A total of 914 patients from 13 studies were included in this meta-analysis. The pooled results suggested that evaluated SNHG6 expression could predict an unfavorable overall survival (OS) (HR = 2.04, 95% CI:1.56~2.52) with no heterogeneity (I2 = 0.0%, p = 0.996). Subgroup analysis indicated a significant association between high SNHG6 expression and shorter OS in studies with digestive system cancers (HR = 2.05, 95%CI: 1.47-2.62), sample size < 70 (HR = 2.70, 95%CI: 1.29-4.11), and univariate and multivariate analysis (HR = 2.04, 95%CI: 1.44-2.64). Moreover, high SNHG6 expression was positively correlated with tumor invasion depth (OR = 1.76, 95%CI: 1.18-2.63), LNM (OR = 1.60, 95%CI: 1.18-2.17), DM (OR = 1.90, 95%CI: 1.37-2.64) and advanced TNM stage (OR = 1.88, 95%CI: 1.36-2.60) in patients with cancers.Conclusions: High lncRNA SNHG6 expression was correlated with tumor invasion depth, LNM, DM, and advanced TNM stage, suggesting that SNHG6 may serve as a promising prognostic biomarker of human cancers.

scholarly journals Clinicopathological and Prognostic Value of Gastric Carcinoma Highly Expressed Transcript 1 in Cancer: A Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-14
Author(s):  
Xi Zhou ◽  
Yanghua Fan ◽  
Yu He ◽  
Anna Mou ◽  
Fu Wang ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Noncoding Rna ◽  
Histological Grade ◽  
Meta Analysis ◽  
Prognostic Indicator ◽  
Tumor Stage ◽  
Poor Overall Survival ◽  
Multiple Cancers ◽  
Hazard Ratios ◽  
High Tumor Stage

Background. Long noncoding RNA gastric cancer highly expressed transcript 1 (lncRNA GHET1) is often reported to be abnormally expressed in multiple cancers, but the situation is different in different cancers. Therefore, a meta-analysis is necessary to clarify the value of lncRNA GHET1 as a prognostic indicator in cancer. Methods. Relevant research studies on lncRNA GHET1 and cancer were retrieved from three electronic literature databases of Web of Science, PubMed, and OVID. Meanwhile, hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to explore the relationship between lncRNA GHET1 expression and survival of cancer patients. The odds ratios (ORs) and 95% CIs were calculated to assess the association of lncRNA GHET1 expression with pathological parameters of cancer patients. Results. The meta-analysis included a total of 11 studies involving 714 cancer patients. The pooled HR suggests that high lncRNA GHET1 expression is associated with poor overall survival. In addition, high expression of lncRNA GHET1 was found to be associated with larger tumor size, poor histological grade, high tumor stage, lymph node metastasis, and distant metastasis. Conclusions. High lncRNA GHET1 expression can predict poor survival and pathological parameters. And lncRNA GHET1 could serve as a new indicator in multiple cancers.

scholarly journals Yes-Associated Protein 1 as a Novel Prognostic Biomarker for Gastrointestinal Cancer: A Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Luo Zhang ◽  
Xing Song ◽  
Xiaodong Li ◽  
Changping Wu ◽  
Jingting Jiang
Keyword(s):  
Gastrointestinal Cancer ◽  
Poor Prognosis ◽  
Web Of Science ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
Hippo Pathway ◽  
Cochrane Library ◽  
Prognostic Effect ◽  
Hazard Ratios ◽  
The Relationship

Background. Yes-associated protein 1 (YAP1) is an effector of Hippo pathway, which plays a significant role in cell proliferation and tumor progression. The relationship between YAP1 and gastrointestinal cancer has been explored in many previous studies. We conducted a meta-analysis to explore the prognostic effect of YAP1 in patients with gastrointestinal cancer.Methods. A systematic search was performed through the PubMed, Web of Science, Embase, and Cochrane library databases to collect eligible studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to evaluate the relationship between YAP1 expression and gastrointestinal cancer clinical outcomes.Results. A total of 2941 patients from 18 studies were enrolled. The results showed that elevated YAP1 expression predicted a poor prognosis in gastrointestinal cancer (HR = 1.56; 95% CI: 1.29-1.89;P< 0.001). Subgroup analyses indicated significant association between YAP1 overexpression and shorter OS of patients with esophageal squamous cell carcinoma (HR = 1.85; 95% CI: 1.25-2.73;P= 0.002), gastric cancer (HR = 1.41,95% CI: 1.02-1.95;P= 0.037), and colorectal cancer (pooled HR = 1.75; 95% CI: 1.42-2.15;P< 0.001). However, YAP1 expression did not affect DFS of patients with gastrointestinal cancer (pooled HR = 1.33; 95% CI: 0.95-1.88;P= 0.101).Conclusion. Elevated YAP1 expression in patients with gastrointestinal cancer might be related to shorter OS. YAP1 protein could serve as a potential predictor of poor prognosis in gastrointestinal cancer.

scholarly journals Clinicopathological and Prognostic Value of SNHG6 in Cancers: a Systematic Review and a Meta-analysis

2020 ◽  
Author(s):  
Shuo Zhang ◽  
Dandan Qiu ◽  
Xiaohong Xie ◽  
Yong Shen
Keyword(s):  
Tumor Invasion ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Tnm Stage ◽  
Invasion Depth ◽  
Clinical Value ◽  
Human Cancers ◽  
Hazard Ratios ◽  
Non Coding Rna ◽  
Tumor Invasion Depth

Abstract Background The long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG6) is dysregulated in various malignant tumor. However, a definite conclusion on the clinical value of lncRNA SNHG6 expression in human cancers has not been determined. The purpose of the present meta-analysis was to comprehensively elucidate the association between SNHG6 expression and clinical outcomes in cancers. Methods A systematic search was performed through the PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wangfang databases for relevant studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were collected to estimate the prognostic value, and the odds ratios (ORs) with 95% CIs were used to evaluate the relationship between lncRNA SNHG6 expression and clinicopathological features, including tumor invasion depth, lymph node metastasis (LNM), distance metastasis (DM), and TNM stage. Results A total of 914 patients from 13 studies were included in this meta-analysis. The pooled results suggested that evaluated SNHG6 expression could predict an unfavorable overall survival (OS) (HR = 2.04, 95% CI:1.56~2.52) with no heterogeneity ( I 2 = 0.0%, p = 0.996). Subgroup analysis indicated a significant association between high SNHG6 expression and shorter OS in studies with digestive system cancers (HR = 2.05, 95%CI: 1.47-2.62), sample size < 70 (HR = 2.70, 95%CI: 1.29-4.11), and univariate and multivariate analysis (HR = 2.04, 95%CI: 1.44-2.64). Moreover, high SNHG6 expression was positively correlated with tumor invasion depth (OR = 1.76, 95%CI: 1.18-2.63), LNM (OR = 1.60, 95%CI: 1.18-2.17), DM (OR = 1.90, 95%CI: 1.37-2.64) and advanced TNM stage (OR = 1.88, 95%CI: 1.36-2.60) in patients with cancers. Conclusions High lncRNA SNHG6 expression was correlated with tumor invasion depth, LNM, DM, and advanced TNM stage, suggesting that SNHG6 may serve as a promising prognostic biomarker of human cancers.

scholarly journals The Prognostic Value of LncRNA SLNCR1 in Cancers: A Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Lele Cong ◽  
Hongyan Sun ◽  
Miao Hao ◽  
Qian Sun ◽  
Yang Zheng ◽  
...  
Keyword(s):  
Tumor Size ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Distant Metastases ◽  
Tumor Stage ◽  
Cochrane Library ◽  
Advanced Tumor Stage ◽  
Multiple Cancer ◽  
Advanced Tumor ◽  
Hazard Ratios

Objective. This meta-analysis was performed to identify the prognostic value of SLNCR1 in multiple cancer types. Methods. Electronic databases, including PubMed, EMBASE, and Web of Science, Cochrane Library, Medline, BioMed Central, Springer, Science Direct, and China National Knowledge Internet (CNKI), were searched for relevant studies up to August 2021, and the hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated to assess the relationship between SLNCR1 expression and overall survival (OS). Results. 12 studies with a total of 1155 patients with 9 different types of cancers were included in this meta-analysis. The pooled HR indicates that high SLNCR1 expression represented poorer prognosis of cancer (HR = 2.11, 95% CI: 1.59–2.80, I2 = 0%, P < 0.00001 ). Additionally, high SLNCR1 expression was correlated with TNM stage (odds ratio (OR): 1.72, 95% CI: 1.08–2.74, I2 = 62%, P = 0.02 ), lymph node metastasis (LNM) (OR:2.42, 95% CI: 1.61–3.64, I2 = 55%, P < 0.0001 ), and distant metastases (DM) (OR: 2.30, 95% CI: 1.50–3.55, I2 = 27%, P = 0.0002 ). However, no evidence was found for a relationship between SLNCR1 expression and clinical features such as tumor size (OR: 1.71, 95% CI: 0.93–3.14, I2 = 71%, P = 0.09 ), age (OR: 0.86, 95% CI: 0.68–1.08, I2 = 0%, P = 0.19 ), or gender (OR: 1.07, 95% CI: 0.64–1.81, I2 = 55%, P = 0.79 ). Conclusion. Our findings found that high SLNCR1 expression was associated with poor OS, advanced tumor stage, tumor size, LNM, and DM in multiple cancers, indicating that SLNCR1 may serve as a potential prognostic biomarker for cancer patients in China.

scholarly journals The prognostic utility and clinical outcomes of MNX1-AS1 expression in cancers: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Juan Li ◽  
Wen Jin ◽  
Zhengyu Zhang ◽  
Jingjing Chu ◽  
Hui Yang ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Clinical Outcomes ◽  
Web Of Science ◽  
Prognostic Biomarker ◽  
Meta Analysis ◽  
High Expression ◽  
Hazard Ratios ◽  
Prognostic Utility ◽  
The Relationship ◽  
Worse Prognosis

Abstract Background: Recently, emerging studies have identified that MNX1-AS1 highly expressed among variety of cancers and related with worse prognosis of cancer patients. The purpose of this study was to evaluate the relationship between MNX1-AS1 expression with clinical features and prognosis in different cancers. Methods: In this study, we searched the Web of Science, PubMed, CNKI, and Wanfang databases to find relevant studies of MNX1-AS1. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were applied to explore the prognostic and clinical significance of MNX1-AS1. Results: A total of 9 literatures were included in this study, including 882 cancer patients. The results showed that patients with increased MNX-AS1 expression were more likely to develop lymph node metastasis (OR = 5.616, 95%CI: 3.093 - 10.199, P = 0.000) and advanced TNM stage (OR = 4.625, 95%CI: 2.366-9.040, P = 0.000). Moreover, we demonstrated that patients with high expression of MNX1-AS1 had poor OS in different cancers (HR = 1.976, 95%CI: 1.653 - 2.361, P=0.000). In addition, patients with high expression of MNX1-AS1 suffer from worse prognosis in gastric cancer (HR = 2.385, 95% CI: 1.838 - 3.094, P = 0.000) and lung cancer (HR= 1.959, 95%CI: 1.353 - 2.835, P = 0.000). Conclusions: High MNX1-AS1 expression is significantly associated with unfavorable clinical outcomes and it has the potential to serve as a prognostic biomarker in cancer patients.

scholarly journals Prognostic and Clinical Value of CD44 and CD133 in Esophageal Cancer: A Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Aseel Kamil Mohammed Al-mosawi ◽  
Hamid Cheshomi ◽  
Ali Hosseinzadeh ◽  
Maryam M. Matin
Keyword(s):  
Overall Survival ◽  
Esophageal Cancer ◽  
Web Of Science ◽  
Meta Analysis ◽  
Survival Rates ◽  
Clinicopathological Features ◽  
Clinical Value ◽  
Node Metastasis ◽  
Hazard Ratios ◽  
Funnel Plots

Despite the importance of CD44 and CD133 in various cancers, the clinicopathological and prognostic values of these biomarkers in esophageal cancer remain debated. Hence, in this study, we did a meta-analysis to explore the correlation between overexpression of these markers and some clinicopathological features and their influence on the survival of esophageal cancer patients. A search in PubMed and Web of Science (among all articles published up to January 16, 2018) was done using the following keywords: esophageal cancer, CD44, CD133, prominin-1, AC133. Suitable studies, that were selected based on the criteria listed in the Materials and Methods section, were chosen and hazard ratios with 95% confidence intervals were estimated if available. Heterogeneity and sensitivity were also analyzed. Furthermore, publication bias was assessed using funnel plots, Egger, and Begg tests. The study included 1346 patients from 13 related studies. The median rates of marker expressions by immunohistochemistry were 35.7% (30%-76.6%) from 9 studies for CD44 and 31.9% (21%–44.2%) from 5 studies for CD133. The accumulative 5-year overall survival rates of CD44-positive and CD133-positive were 1.59% (1.22-2.06) and 1.27% (0.93-1.73), respectively. Meta-analysis showed that CD44 expression had a significant correlation with 5-year overall survival. CD44 overexpression showed a correlation with some clinicopathological features such as lymph node metastasis, vascular invasion, and recurrence of the disease, while it was not the case for coexpression of CD44 and CD133. In conclusion, CD44 overexpression was associated with a 5-year overall survival rate and thus this biomarker can be a suitable prognostic tool in esophageal cancer.

scholarly journals Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis

2018 ◽  
Vol 33 (3) ◽  
pp. 266-274 ◽  
Author(s):  
Dongjing Zhang ◽  
Zhihong Liu ◽  
Xueru Yin ◽  
Xiaolong Qi ◽  
Bingyun Lu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Prognostic Value ◽  
Clinical Utility ◽  
Web Of Science ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Hazard Ratios

Background: Several studies have been conducted to evaluate the prognostic value of prothrombin induced by vitamin K absence-II (PIVKA-II) overexpression in hepatocellular carcinoma patients treated with curative ablation. However, the results remain controversial. The purpose of this meta-analysis was to explore the correlation between PIVKA-II expression and survival outcomes in these patients. Methods: We performed a systematic literature search in PubMed, EMBASE, Medline, Cochrane Library, and Web of Science to identify the relevant articles investigating the prognostic value of PIVKA-II in patients with hepatocellular carcinoma. Combined hazard ratios (HR) and their 95% confidence intervals (CI) for overall survival and recurrence-free survival were calculated as the analysis endpoints. Results: A total of 15 cohorts encompassing 5647 patients were included. The results indicated that elevated PIVKA-II was significantly associated with poorer overall survival (HR 1.59; 95% CI 1.40, 1.82; P < 0.001) and recurrence-free survival (HR 1.76; 95% CI 1.42, 2.17; P < 0.001). Similar results were observed in the subgroup analysis based on sample size, analytical method, treatment modality, and cut-off value. Conclusions: This meta-analysis suggests that elevated PIVKA-II is a predictor of unfavorable overall survival and recurrence-free survival in hepatocellular carcinoma patients receiving curative ablation. More rigorous studies are warranted to confirm the clinical utility of PIVKA-II in determining hepatocellular carcinoma prognosis.

Sign in / Sign up

Export Citation Format

Share Document